AbCellera Biologics Inc

NASDAQ:ABCL   3:59:24 PM EDT
27.95
-0.40 (-1.41%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)7.53B
Current PE63.34
Forward PE 20.86
2yr Forward PE 54.8
See more stats
Estimates Current Quarter
Revenue$200.54 Million
Adjusted EPS$0.41
See more estimates
10-Day MA$29.00
50-Day MA$36.19
200-Day MAN/A
See more pivots

AbCellera Biologics, Inc. Stock, NASDAQ:ABCL

2215 Yukon Street, Vancouver, British Columbia V5Y 0A1
Canada
Phone: +1.604.559.9005
Number of Employees: 107

Description

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Vronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.